ANI Pharmaceuticals, Inc. has revised up its full-year guidance for 2023 following a record quarter, as the firm’s pivotal Cortrophin gel (repository corticotropin injection) 80 U/ml launch and scale-up of its generics business – boosted by competitor supply disruption during Q1 – continue to propel the firm forward.
The company ultimately raised its annual net revenue guidance to $385m-$410m, from a previous estimate of $360m-$385m. It also increased...







